Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-II-GP
- Development stage
- Preclinical
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
AD-II-GP is a replication-deficient adenoviral vaccine designed to express a viral antigen linked to an invariant chain. It functions as a tumor vaccine candidate, primarily investigated in murine melanoma models. The drug aims to stimulate a robust and prolonged tumor-specific CD8 T cell response, which is crucial for achieving tumor regression and long-term survival. Its therapeutic effect is enhanced when combined with agonistic anti-CD40 monoclonal antibodies and anti-CTLA-4 monoclonal antibodies.
- Other names
- replication deficient adenovirus expressing a viral antigen linked to invariant chain
Beyond the preview
Go deeper on AD-II-GP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-II-GP.